Morning Read: Hatteras Venture Partners raises $90M for fifth fund, BioMarin in $570M breast cancer drug deal
BioMarin Pharmaceutials is selling the global license for its PARP inhibitor talazoparibin to Medivation in a $570 million deal. Hatteras Venture Partners has raised $90 million as part of its first close for its fifth venture fund.